These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15961980)

  • 1. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Jung HR; Lim KS; Jang IJ; Shin SG
    Clin Pharmacol Ther; 2005 Jun; 77(6):486-94. PubMed ID: 15961980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
    Chung JY; Cho JY; Yu KS; Kim JR; Lim KS; Sohn DR; Shin SG; Jang IJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):595-600. PubMed ID: 17687269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampin reduces plasma concentrations and effects of zolpidem.
    Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
    Park JY; Kim KA; Park PW; Park CW; Shin JG
    Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam.
    Samara EE; Granneman RG; Witt GF; Cavanaugh JH
    J Clin Pharmacol; 1997 May; 37(5):442-50. PubMed ID: 9156377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.
    Metz DC; Devlin JW; Vakily M; Atkinson S; Lloyd E
    Pharmacotherapy; 2008 Mar; 28(3):301-7. PubMed ID: 18294109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients.
    Masica AL; Girard TD; Wilkinson GR; Thomason JW; Truman Pun B; Nair UB; Light RW; Canonico AE; Dunn J; Pandharipande P; Shintani AK; Ely EW
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):218-31. PubMed ID: 17996661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.
    Barnes BJ; Gerst C; Smith JR; Terrell AR; Mullins ME
    Pharmacotherapy; 2006 Jan; 26(1):23-33. PubMed ID: 16422667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
    Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
    Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of experimentally induced sleep disturbance on the pharmacokinetics of lorazepam in healthy volunteers.
    Kotegawa T; Tsutsumi K; Imai H; Ohashi K; Nakano S
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):519-24. PubMed ID: 24755136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication.
    Mijderwijk H; Klimek M; van Beek S; van Schaik RH; Duivenvoorden HJ; Stolker RJ
    Anesth Analg; 2016 Nov; 123(5):1109-1115. PubMed ID: 27622723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal from lorazepam in critically ill children.
    Dominguez KD; Crowley MR; Coleman DM; Katz RW; Wilkins DG; Kelly HW
    Ann Pharmacother; 2006 Jun; 40(6):1035-9. PubMed ID: 16720707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam.
    Yamazaki A; Kumagai Y; Fujita T; Hasunuma T; Yokota S; Maeda M; Otani Y; Majima M
    J Clin Pharm Ther; 2007 Feb; 32(1):31-9. PubMed ID: 17286787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.
    Ujiie Y; Fukasawa T; Yasui-Furukori N; Suzuki A; Tateishi T; Otani K
    Ther Drug Monit; 2006 Jun; 28(3):299-302. PubMed ID: 16778710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.